New glucose monitoring device contender arises, unveiling preliminary results
Implantable Continuous Glucose Monitoring Devices: Glucotrack and Senseonics Offer Innovative Solutions
Two companies, Glucotrack and Senseonics, are revolutionising the field of continuous glucose monitoring (CGM) with their implantable devices. Each offers unique features, with key differences in placement, longevity, and regulatory clearance.
Glucotrack's device, a pioneering venous implant, is surgically inserted into a vein, measuring blood glucose levels directly. This approach, unlike most CGMs that measure glucose in the interstitial fluid, may provide more accurate blood glucose data and reduce common CGM limitations related to hydration and other factors. The device is expected to last up to three years, but this has not yet been proven.
On the other hand, Senseonics' Eversense 365, a well-established implantable CGM, is implanted under the skin and measures interstitial fluid glucose. It is approved for up to one year of wear, with the sensor renewed annually through a minor procedure. Notably, it integrates with advanced insulin delivery algorithms and systems, supporting hybrid closed-loop systems.
Regulatory clearance varies between the two. Glucotrack is yet to receive FDA clearance, with market availability anticipated around 2028. In contrast, Senseonics' latest model supports 365-day wear with improved patch, and is FDA-cleared and commercially available.
Both devices reflect the evolving trend towards longer implant durations and less maintenance in the implantable CGM market. This development is aimed at improving diabetes care with low-profile, maintenance-light devices that support better glycemic control.
Senseonics anticipates a doubling of sales in 2025, highlighting the growing interest in these innovative implantable CGMs. As the landscape continues to evolve, both Glucotrack and Senseonics are poised to make significant contributions to the management of diabetes.
[1] [Source] [3] [Source]
- These implantable continuous glucose monitoring devices from Glucotrack and Senseonics are leveraging advanced medtech and AI to revolutionize health-and-wellness for patients with medical-conditions like diabetes.
- The application of analytics and science in these devices is expected to enhance safety and effectiveness, catering to the latest news and events in the medtech industry.
- The FDA's role in the clearance of these devices, such as Glucotrack and Senseonics’ Eversense 365, is crucial in ensuring the technology meets the required safety and performance standards.
- With less maintenance and longer implant durations, these devices exemplify the growing trend towards innovation in the medical-conditions management space, backed by advancements in technology.
- Notably, both Glucotracker and Senseonics' devices are anticipated to significantly impact the healthcare sector by offering unparalleled accuracy in measurements, ultimately promoting healthier lifestyles and better patient outcomes.
- The increasing demand for these implantable devices, as exemplified by Senseonics' projected sales increase in 2025, highlights the growing need for advanced solutions in the field of medical-conditions management and health-and-wellness.
